PE20070188A1 - Formulaciones de estrogenos conjugados y bazedoxifeno - Google Patents
Formulaciones de estrogenos conjugados y bazedoxifenoInfo
- Publication number
- PE20070188A1 PE20070188A1 PE2006000757A PE2006000757A PE20070188A1 PE 20070188 A1 PE20070188 A1 PE 20070188A1 PE 2006000757 A PE2006000757 A PE 2006000757A PE 2006000757 A PE2006000757 A PE 2006000757A PE 20070188 A1 PE20070188 A1 PE 20070188A1
- Authority
- PE
- Peru
- Prior art keywords
- weight
- pharmaceutical formulation
- formulation
- bazedoxifene
- formulations
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 229940036507 conjugated estrogen and bazedoxifene Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 7
- 238000009472 formulation Methods 0.000 abstract 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 abstract 1
- 206010065687 Bone loss Diseases 0.000 abstract 1
- 239000003963 antioxidant agent Substances 0.000 abstract 1
- 230000003078 antioxidant effect Effects 0.000 abstract 1
- UCJGJABZCDBEDK-UHFFFAOYSA-N bazedoxifene Chemical compound C=1C=C(OCCN2CCCCCC2)C=CC=1CN1C2=CC=C(O)C=C2C(C)=C1C1=CC=C(O)C=C1 UCJGJABZCDBEDK-UHFFFAOYSA-N 0.000 abstract 1
- 239000013522 chelant Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229940035811 conjugated estrogen Drugs 0.000 abstract 1
- 238000002657 hormone replacement therapy Methods 0.000 abstract 1
- 230000003020 moisturizing effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA EN FORMA DE TABLETA QUE COMPRENDE: A) UN NUCLEO QUE COMPRENDE ESTROGENOS CONJUGADOS EN UNA CANTIDAD DESDE 0.1-1,0 mg; B) UNA COBERTURA QUE COMPRENDE BAZEDOXIFENO DE BASE LIBRE EN UNA CANTIDAD DE 5-25 mg. EL NUCLEO COMPRENDE DESDE CERCA DE 45-80% POR PESO DE LA FORMULACION FARMACEUTICA Y LA COBERTURA CONSTA DE: 1) UN COMPONENTE DE RELLENO DE 6-12% POR PESO DE LA FORMULACION FARMACEUTICA; 2) UN AGLOMERANTE DE CERCA DE 6% DE LA FORMULACION FAMACEUTICA; 3) UN HUMECTANTE DE 0,01-3% POR PESO DE LA FORMULACION FARMACEUTICA; 4) UN ANTIOXIDANTE DE CERCA DE 0,5% POR PESO DE LA FORMULACION FARMACEUTICA; 5) ACETATO DE BAZEDOXIFENO, DE 2-6% POR PESO DE LA FORMULACION FARMACEUTICA; 6) UN QUELANTE DE 0-0,1% POR PESO DE LA FORMULACION FARMACEUTICA. DICHA FORMULACION ES UTIL EN LA TERAPIA DE REEMPLAZO HORMONAL PARA LA PREVENCION DE PERDIDA OSEA EN MUJERES POSTMENOPAUSICAS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69488905P | 2005-06-29 | 2005-06-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20070188A1 true PE20070188A1 (es) | 2007-03-16 |
Family
ID=37401610
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2006000757A PE20070188A1 (es) | 2005-06-29 | 2006-06-28 | Formulaciones de estrogenos conjugados y bazedoxifeno |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20070003623A1 (es) |
| EP (1) | EP1898888A2 (es) |
| JP (1) | JP2008545012A (es) |
| KR (1) | KR20080031037A (es) |
| CN (1) | CN101252921A (es) |
| AR (1) | AR054806A1 (es) |
| AU (1) | AU2006263638A1 (es) |
| BR (1) | BRPI0612586A2 (es) |
| CA (1) | CA2613102A1 (es) |
| CR (1) | CR9597A (es) |
| EC (1) | ECSP078057A (es) |
| IL (1) | IL188223A0 (es) |
| NI (1) | NI200700331A (es) |
| NO (1) | NO20080002L (es) |
| PA (1) | PA8684501A1 (es) |
| PE (1) | PE20070188A1 (es) |
| RU (1) | RU2395286C2 (es) |
| TW (1) | TW200738283A (es) |
| WO (1) | WO2007002823A2 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007532557A (ja) * | 2004-04-08 | 2007-11-15 | ワイス | バゼドキシフェンアセテート固体分散物製剤 |
| JP2010511062A (ja) * | 2006-11-29 | 2010-04-08 | ワイス エルエルシー | エストロゲン／ｓｅｒｍおよびエストロゲン／プロゲスチン二層錠剤 |
| AU2008206476A1 (en) * | 2007-01-12 | 2008-07-24 | Wyeth | Tablet-in-tablet compositions |
| PE20090100A1 (es) * | 2007-03-30 | 2009-02-26 | Wyeth Corp | Metodos de separacion y deteccion de acetato de bacedoxifeno en composiciones farmaceuticas |
| CA2775599A1 (en) | 2009-10-27 | 2011-05-12 | Wyeth Llc | Bazedoxifene formulations with antioxidants |
| EP2560617A2 (en) * | 2010-04-20 | 2013-02-27 | Cilpa Limited | Pharmaceutical compositions |
| US8615061B2 (en) * | 2010-07-29 | 2013-12-24 | Entropic Communications, Inc. | Method and apparatus for cross polarization and cross satellite interference cancellation |
| SG194943A1 (en) * | 2011-05-13 | 2013-12-30 | Emotional Brain Bv | Drug delivery system |
| CN104013630B (zh) * | 2014-05-23 | 2018-08-21 | 合肥九研医药科技开发有限公司 | 一种复方醋酸巴多昔芬雌激素组合物 |
| RS62844B1 (sr) | 2015-06-18 | 2022-02-28 | Estetra Srl | Orodisperzibilna dozna jedinica koja sadrži komponentu estetrola |
| CA3178291A1 (en) | 2016-08-05 | 2018-04-12 | Estetra Srl | Method for the management of dysmenorrhea and menstrual pain |
| WO2018182205A1 (ko) * | 2017-03-30 | 2018-10-04 | 한미약품 주식회사 | 바제독시펜 아세테이트를 함유하는 안정화된 약제학적 조성물 |
| JOP20200260A1 (ar) * | 2018-04-19 | 2019-10-19 | Estetra Sprl | مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث |
| TWI801561B (zh) | 2018-04-19 | 2023-05-11 | 比利時商依思特拉私人有限責任公司 | 化合物及其用於緩解絕經相關症狀的用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2565115A (en) * | 1948-10-28 | 1951-08-21 | Squibb & Sons Inc | Method of obtaining a conjugated estrogen preparation |
| US2720483A (en) * | 1951-02-21 | 1955-10-11 | Olin Mathieson | Method of obtaining a conjugatedestrogen preparation |
| US5210081A (en) * | 1992-02-26 | 1993-05-11 | American Home Products Corporation | Alkali metal 8,9-dehydroestrone sulfate esters |
| US5759577A (en) * | 1995-01-17 | 1998-06-02 | American Home Products Corporation | Controlled release of steroids from sugar coatings |
| US5547948A (en) * | 1995-01-17 | 1996-08-20 | American Home Products Corporation | Controlled release of steroids from sugar coatings |
| US5998402A (en) * | 1996-04-19 | 1999-12-07 | American Home Products Corporation | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents |
| US6479535B1 (en) * | 1998-05-15 | 2002-11-12 | Wyeth | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations |
| CN1390126B (zh) * | 1999-07-06 | 2012-06-13 | 恩多研究公司 | 选择性雌激素受体调节剂在制备用于治疗或降低肥胖症发展危险性的药物中的用途 |
| AR029538A1 (es) * | 2000-07-06 | 2003-07-02 | Wyeth Corp | Composiciones farmaceuticas de agentes estrogenicos |
| US20040063692A1 (en) * | 2002-06-13 | 2004-04-01 | Wyeth | Bazedoxifene treatment regimens |
| US7683051B2 (en) * | 2004-04-07 | 2010-03-23 | Wyeth | Crystalline polymorph of bazedoxifene acetate |
| WO2005100314A1 (en) * | 2004-04-07 | 2005-10-27 | Wyeth | Crystalline polymorph of bazedoxifene acetate |
| BRPI0509385A (pt) * | 2004-04-08 | 2007-09-18 | Wyeth Corp | composto, composição, métodos de preparar o sal, ea dispensão sólida, de tratar um mamìfero tendo uma doença ou sìndrome associadas com a deficiência de estrogênio ou excesso de estrogênio, uma doença ou distúrbio associados com a proliferação ou desenvolvimento anormal dos tecidos endometriais, de tratar cáncer de mama em um mamìfero, e uma mulher pós-menopáusica quanto a um ou mais distúrbios vasomotores, de reduzir colesterol, e de inibir perda óssea em um mamìfero, dispersão sólida, e, uso de um composto |
| JP2007532557A (ja) * | 2004-04-08 | 2007-11-15 | ワイス | バゼドキシフェンアセテート固体分散物製剤 |
-
2006
- 2006-06-28 CN CNA2006800313156A patent/CN101252921A/zh active Pending
- 2006-06-28 RU RU2007148071/15A patent/RU2395286C2/ru not_active IP Right Cessation
- 2006-06-28 CA CA002613102A patent/CA2613102A1/en not_active Abandoned
- 2006-06-28 JP JP2008520286A patent/JP2008545012A/ja not_active Withdrawn
- 2006-06-28 EP EP06785833A patent/EP1898888A2/en not_active Withdrawn
- 2006-06-28 BR BRPI0612586-7A patent/BRPI0612586A2/pt not_active IP Right Cessation
- 2006-06-28 PE PE2006000757A patent/PE20070188A1/es not_active Application Discontinuation
- 2006-06-28 TW TW095123252A patent/TW200738283A/zh unknown
- 2006-06-28 US US11/478,400 patent/US20070003623A1/en not_active Abandoned
- 2006-06-28 WO PCT/US2006/025348 patent/WO2007002823A2/en active Application Filing
- 2006-06-28 KR KR1020087002416A patent/KR20080031037A/ko not_active Ceased
- 2006-06-28 AU AU2006263638A patent/AU2006263638A1/en not_active Abandoned
- 2006-06-28 AR ARP060102789A patent/AR054806A1/es unknown
- 2006-06-29 PA PA20068684501A patent/PA8684501A1/es unknown
-
2007
- 2007-12-17 CR CR9597A patent/CR9597A/es not_active Application Discontinuation
- 2007-12-18 IL IL188223A patent/IL188223A0/en unknown
- 2007-12-18 NI NI200700331A patent/NI200700331A/es unknown
- 2007-12-27 EC EC2007008057A patent/ECSP078057A/es unknown
-
2008
- 2008-01-02 NO NO20080002A patent/NO20080002L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US20070003623A1 (en) | 2007-01-04 |
| CN101252921A (zh) | 2008-08-27 |
| WO2007002823A2 (en) | 2007-01-04 |
| ECSP078057A (es) | 2008-01-23 |
| PA8684501A1 (es) | 2007-01-17 |
| IL188223A0 (en) | 2008-03-20 |
| AU2006263638A1 (en) | 2007-01-04 |
| BRPI0612586A2 (pt) | 2010-11-23 |
| CA2613102A1 (en) | 2007-01-04 |
| AR054806A1 (es) | 2007-07-18 |
| NO20080002L (no) | 2008-03-12 |
| CR9597A (es) | 2008-03-06 |
| NI200700331A (es) | 2009-02-16 |
| RU2395286C2 (ru) | 2010-07-27 |
| WO2007002823A3 (en) | 2007-08-09 |
| JP2008545012A (ja) | 2008-12-11 |
| KR20080031037A (ko) | 2008-04-07 |
| TW200738283A (en) | 2007-10-16 |
| EP1898888A2 (en) | 2008-03-19 |
| RU2007148071A (ru) | 2009-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20070188A1 (es) | Formulaciones de estrogenos conjugados y bazedoxifeno | |
| PE20070208A1 (es) | Anticoncepcion oral con trimegestona | |
| MY169516A (en) | Pharmaceutical composition containing a tetrahydrofolic acid | |
| PE20070327A1 (es) | Composicion que comprende una progestina y un estrogeno | |
| AR057060A1 (es) | Composiciones de tanaproget que contienen etinil estradiol | |
| CO6400186A2 (es) | Tabletas de acetato de ulipristal | |
| RS52463B (en) | PHARMACEUTICAL DOSAGE FORMS ABUSE-RESISTANT CONTAINING OPIOID ANALGETIC | |
| PT2038290E (pt) | Moduladores de receptor do tipo toll 7 | |
| NZ599847A (en) | Pharmaceutical composition comprising a glp-1 agonist and methionine | |
| WO2007048219A3 (en) | Sustained drug release composition | |
| NZ605176A (en) | Pharmaceutical composition comprising drospirenone and contraceptive kit | |
| UA96302C2 (en) | Solid dosage form comprising 2-ethoxy-1-{[2'-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl]methyl}-1h-benzimidazole-7-carboxylic acid | |
| MX2009002180A (es) | Metodo de inhibicion de la depresion respiratoria mediante el uso de moduladores alostericos positivos del receptor ampa. | |
| GT200800107A (es) | Formulaciones orales que comprenden tigeciclina | |
| PE20060275A1 (es) | Composicion farmaceutica que contiene progestina y estrogeno para el tratamiento de trastorno disforico premenstrual | |
| CR10289A (es) | "estratrienos 9-alfa-sustituidos como estrogenos de eficacia selectiva"(divisional) | |
| UA87841C2 (ru) | Композиция, которая содержит амброксол, для местного применения | |
| MX2010006259A (es) | Piperazinas como agentes antiobesidad. | |
| PE20060368A1 (es) | Anticonceptivo hormonal conteniendo una combinacion de etinilestradiol y acetato de clormadinona | |
| EA201000097A1 (ru) | 8-бета-замещенные эстратриены в качестве селективно активных эстрогенов | |
| UY32005A (es) | Derivados de estratrieno que comprenden bioisósteros heterocíclicos para el anillo fenólico a | |
| EP1404344A2 (en) | Bone anabolic compounds and methods of use | |
| WO2009042632A3 (en) | Combination therapy related to serotonin dual action compounds | |
| MX2008002272A (es) | Compuestos de ciclopropilo y composiciones para suministrar agentes activos. | |
| BR0309621A (pt) | Uso de estrógenos conjugados em combinação com trimegestona na terapia de substituição de hormÈnios |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FX | Voluntary withdrawal |